Your browser doesn't support javascript.
loading
TET protein inhibitors: Potential and limitations.
Kaplánek, Robert; Kejík, Zdenek; Hajduch, Jan; Veselá, Katerina; Kucnirová, Katerina; Skalicková, Markéta; Venhauerová, Anna; Hosnedlová, Bozena; Hromádka, Róbert; Dytrych, Petr; Novotný, Petr; Abramenko, Nikita; Antonyová, Veronika; Hoskovec, David; Babula, Petr; Masarík, Michal; Martásek, Pavel; Jakubek, Milan.
Afiliación
  • Kaplánek R; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Kejík Z; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Hajduch J; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Veselá K; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Kucnirová K; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Skalicková M; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Venhauerová A; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Hosnedlová B; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Hromádka R; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Dytrych P; 1st Department of Surgery-Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 2, 121 08 Prague, Czech Republic.
  • Novotný P; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Abramenko N; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Antonyová V; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
  • Hoskovec D; 1st Department of Surgery-Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 2, 121 08 Prague, Czech Republic.
  • Babula P; Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic.
  • Masarík M; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenic
  • Martásek P; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic. Electronic address: pavel.martasek@lf1.cuni.cz.
  • Jakubek M; BIOCEV, First Faculty of Medicine, Charles University, Prumyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
Biomed Pharmacother ; 166: 115324, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37598475
ABSTRACT
TET proteins (methylcytosine dioxygenases) play an important role in the regulation of gene expression. Dysregulation of their activity is associated with many serious pathogenic states such as oncological diseases. Regulation of their activity by specific inhibitors could represent a promising therapeutic strategy. Therefore, this review describes various types of TET protein inhibitors in terms of their inhibitory mechanism and possible applicability. The potential and possible limitations of this approach are thoroughly discussed in the context of TET protein functionality in living systems. Furthermore, possible therapeutic strategies based on the inhibition of TET proteins are presented and evaluated, especially in the field of oncological diseases.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dioxigenasas Idioma: En Revista: Biomed Pharmacother Año: 2023 Tipo del documento: Article País de afiliación: República Checa

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dioxigenasas Idioma: En Revista: Biomed Pharmacother Año: 2023 Tipo del documento: Article País de afiliación: República Checa
...